DexCom (NASDAQ:DXCM) was upgraded by equities researchers at Robert W. Baird from a “neutral” rating to an “outperform” rating in a report released on Friday.

Several other analysts have also recently commented on DXCM. BidaskClub raised DexCom from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 12th. BMO Capital Markets raised their target price on DexCom to $74.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 12th. Jefferies Group raised their target price on DexCom from $58.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. Northland Securities cut DexCom from a “market perform” rating to an “under perform” rating and set a $85.00 target price for the company. in a research report on Thursday, January 4th. Finally, Barclays reaffirmed a “hold” rating and issued a $60.00 target price on shares of DexCom in a research report on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $67.03.

How to Become a New Pot Stock Millionaire

Shares of DexCom (NASDAQ DXCM) opened at $66.74 on Friday. The company has a market capitalization of $5,890.58, a price-to-earnings ratio of -113.12 and a beta of 0.27. The company has a quick ratio of 5.04, a current ratio of 5.36 and a debt-to-equity ratio of 0.78. DexCom has a 12-month low of $42.62 and a 12-month high of $86.32.

DexCom (NASDAQ:DXCM) last issued its earnings results on Tuesday, February 27th. The medical device company reported $0.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.07. The business had revenue of $221.00 million during the quarter, compared to analysts’ expectations of $217.82 million. DexCom had a negative return on equity of 13.99% and a negative net margin of 6.99%. research analysts expect that DexCom will post -0.56 EPS for the current year.

In related news, EVP Richard Doubleday sold 1,638 shares of DexCom stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $56.32, for a total transaction of $92,252.16. Following the completion of the sale, the executive vice president now owns 65,049 shares of the company’s stock, valued at $3,663,559.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Terrance H. Gregg sold 10,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total value of $568,600.00. Following the completion of the sale, the insider now directly owns 484,559 shares of the company’s stock, valued at approximately $27,552,024.74. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,908 shares of company stock valued at $2,056,635. Insiders own 1.70% of the company’s stock.

Several large investors have recently made changes to their positions in DXCM. JPMorgan Chase & Co. lifted its position in shares of DexCom by 143.8% in the third quarter. JPMorgan Chase & Co. now owns 2,358,507 shares of the medical device company’s stock worth $107,170,000 after buying an additional 7,738,678 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of DexCom by 29.2% in the third quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock worth $431,510,000 after buying an additional 1,991,094 shares during the last quarter. Brown Advisory Inc. lifted its position in shares of DexCom by 57.2% in the third quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after buying an additional 1,515,134 shares during the last quarter. Bridger Management LLC acquired a new stake in shares of DexCom in the fourth quarter worth about $48,826,000. Finally, OppenheimerFunds Inc. lifted its position in shares of DexCom by 96.5% in the fourth quarter. OppenheimerFunds Inc. now owns 1,495,535 shares of the medical device company’s stock worth $85,829,000 after buying an additional 734,325 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: “DexCom (DXCM) Raised to “Outperform” at Robert W. Baird” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/dexcom-dxcm-raised-to-outperform-at-robert-w-baird/1959526.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.